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Results areshowninthetable.
OveralltherewerecorrelationsbetweenpeakV02 andstrength(r= O.46,
p < 0.0001),quadsCSA(r = 0.355,p = 0.0002)and20 minutefatigue(r=
0.4p < 0.001)andbetweentheVE/VC02slopeandstrength(r= 0.345,p <
0.0001)quadsCSA(r= 0.28,p =0.005)and20 minutefatigue(r= 0.25,p=
0.006).Cone/usiorrs.’CHFpatientsareweakbacauseofatrophyandreduced




m7522 Relation Between Low-lntenaity Exerciae Capacity
and Quality of Life in Patienta With Mild to Moderate
Congestive Heatl Failure
D.Weilenmann,H.P.Brunner-iaRocca,B.LuII,M.Schlumpf,W,Kiowski,
F.Follath.Division of Cardiology Depatiment of Medicine, Univeraiiy
Hospital, Zudch, Swlt.zerland
Exercisecepacify(EC)is an acceptedprognosticfactorin patients(P)with
congestiveheartfailure(CHF).However,iksrelationto measuresof quelify
of life (QOL)suchas the “Minnesotalivingwithheartfailurequestionnaire”
(MC!)is IXJOrlydefined.Therefore,we repeatedlyassessedtheMQandlow-
intensityandmaximalECduringtreatmentwithdifferentdosesofenalaprilin
24P (age:52* 11years)with impairedsystolicleftventricularfunction(EF





= -0.11, ns).A moderatecorrelationexistedbetwaenSMQandTED(r= –
0.23,p < 0.05),whereasSMQandthe02-deficit(r= O.43,p < 0.001)aswell
asthe meanresponsetime(MRT[tvz of increasein 02-uptake];r = 0.46,p
< 0.001)weramoretightlylinkedduringIow-intansityexercise.NYHAclass
correlatedwithallparameters(bestwithSMQ:r =0.45,ps 0.001andlowest
withpV02:r= – 0.33,p < 0.006).
Conclusion: P do not seemto noticethe extentof impairmentin pVOZ
duringdaily life. In contrast,the Oz-deficitcorrelatedbetterwith the SMQ
indicatingthatincreasesof Iow-int.ensityexerciseperformanceareperceived
asbetterQOL.Ourdata,therefore,suppori the concept of using a submax-
imal stress test to evaluate the extent of impairment during daily life, and,
accordingly, measures of QOLin PwithCHF.
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m7523 Clinical Relevence of Arterial Oxygen Saturation
Instability to Detect Breathing Disorders in Chronic
Heart Failure
A. Mortara,G.D.Pinna,R.Maestri,A. Prpa,F.Cobelli,P.Sleight
L.Tavazzi.Division of Cardiology “S. Maugeri” Fourrdation, IRCCS,
Montescano, Pavia, Italx 1John Radcliffe Hospital, Oxford, UK




breathingdisordersandmodulationof Sa02 duringawakeday-time,80 pts




normalraspiratotypatternin 29 pts,while51 hada persistentalterationof
breathing,withatypicalCSin 21anda PBin 30.Overallvariabilityof Sa02
waeobtainadby analysieof thestandarddeviation(SD)of the beat-tobeat
signals.Sa02 wassignificantlyreducedin CSandPB(respectively,93.0*
1.8and 93.8 + 2% vs 94.2 + 1.6%,bothp c 0.02)and SDof Sa02 was
higher(1.5+ 0.6 and0.7+ 0.2%vs 0.4 * 0.1%,p <0.01 andp -=0.03)
as comparedto normals.ControlledventilationeliminatedCSand PBin all
patientswitha significantincreasein Sa02 (CS= +2.5%, p <0.001, PB=
+1.4%,p < 0.01);Sa02 variabilityremainedunchangedin normals,whileit
wasmarkedlyreducedin CSand PB(CS= 0.4 * 0.2%,PB= 0.3 + 0.2’%,
p <0.02 vs baseline).ByR.O.C.it wasfoundthat SDof Sa02 ?1% hada
sensitivityof 86Y0anda specificityof 100%in identifyingCHFpatients with
CS. Thus,in CHF,abnormalitiesof breathingactivitycausaa markedinsta-
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Similar Efficacy (but Different Mechanism) on
Exercise CaDacltv of Losarten (LOS) and Enalanril
(EN) in Chronic Heert Failure (CHF) ““ ‘
M.Guazzi,P.G,Agostoni,G.C.Maranzi,G.Melzi,M.D.Guazzi.Urriversify
of Milan, C.N.R., Milan, Italy
Ameliorationof respiratoryfuncfionandexercisecapacifywithACE-inhibition
inCHFisantagonizedbyaspirin(AS),suggestinga bradykinin-prostaglandin
mediatedeffect.A comparativestudywith EN vs the ATI blocker,LOS,







volumeratio(VDiVp)at peakexerciseweretestedat theendof eachstep.
V02 p 1-r VDiVTP Vc DLCO
PL 15.7*3 572 + 181 0.21 +0.03 3.0 * 0,9 t9+3
EN 18* 4#~ 631 4154s$ 0.20+0.03 3.3 & 0.6 22 k4*5
EN+AS 16+4 590+ 130 0.22 +0.05 3,1 * 0.6 19*4
AS 15+5 579 * 133 0.19+0.05 3.0 * 0.9 le*6
LOS te 44*S 650 + 146#~ 0.19 l0.03$’5 3.0 + 1.0 20 i 3
LOS+AS 17+ 6#5 659 * 13#5 o.le + o.03#5 3.1 * 1.0 20*3
#p< 0.05 vs. PL; $ = p <0.05 vs. EN+AS. Mean valuss (+ 1 SD).
Conclusions.’ Effectivenessof the two drugson exercisecapacity(TT
andV02 p) is similarbutprobablymediatedthroughdifferentmechanisms,
as suggastedby a selectivecounteractionof AS againstEN.Prostglandin
activationoccurswith the ACE-inhibitorand not with the ATI blockerand
importantlyparticipatesin raisinglungdiffusionandfunctionalcapacity.im-
provementin TT andV02 p with LOSis dissociatedfrom significantinflu-
encesonthe respiratoryfunction.
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17’52-51Effects of L~aartanonExerc,ee CaPac,tY,MorbiditY
and Mortality in Patients with Symptomatic Heart
Failure
G.Klinger,N.Jaramillo,H. Ikram,M, Higginbctham,R.Lang,L).Kraus,
L.Washington,D.Sharma,W.Grossman.Merck& Co., /rrc., West Point,
PA, USA
Losartan(L) i$ a specificangiotenainII (Angll)fypa 1 receptorantagonist
whichblocksthe effectsof Angll generatadfrom bothACEand non-ACE
dependentpathways.Thus,LmayblocktheeffecfsofAngllmorecompletely
thananACEinhibitor.Twomulticenter,double-blind,placebc-controlled,ex-
ercisestudieswere parformedto assessthe efficacyand safetyof L in
patientswithheatifailure(HF).PatientswithNYHAClassII-IV HFandejec-
tionfractions40%wererandomizedin a 2:1 ratio(L:placebo[P]).Changes
in maximalexercisetime(ET-primatyendpoint)after12weeksof treatment
were not different between groups.Medianincreases(see)were55 and45





US. (n =351) Int’1(n = 305) Combinsd
L P L P L P
Death 1.7% 3,5% 1,2%* 6,9% 1.4”/0” 5.3%
HF hospitalization 4,2% 6.6% 2,0% 5.3% 3.1”/&* 6.9”A
“ p <0,05 VS.pbo
Cone/usiorr:Comparedto placebo,treatmentwith losartanfor 12weeka
didnotimproveETbutaignificantlyraducedmorbidityandmortalityinpatienta
withheartfailure.
